Literature DB >> 18537678

Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.

H Yang1, K R Landis-Piwowar, D Chen, V Milacic, Q P Dou.   

Abstract

The proteasome is a multicatalytic protease complex that degrades most endogenous proteins including misfolded or damaged proteins to ensure normal cellular function. The ubiquitin-proteasome degradation pathway plays an essential role in multiple cellular processes, including cell cycle progression, proliferation, apoptosis and angiogenesis. It has been shown that human cancer cells are more sensitive to proteasome inhibition than normal cells, indicating that a proteasome inhibitor could be used as a novel anticancer drug. Indeed, this idea has been supported by the encouraging results of the clinical trials using the proteasome inhibitor Bortezomib (Velcade, PS-341), a drug approved by the US Food and Drug Administration (FDA). Several natural compounds, including the microbial metabolite lactacystin, green tea polyphenols, and traditional medicinal triterpenes, have been shown to be potent proteasome inhibitors. These findings suggest the potential use of natural proteasome inhibitors as not only chemopreventive and chemotherapeutic agents, but also tumor sensitizers to conventional radiotherapy and chemotherapy. In this review, we will summarize the structures and biological activities of the proteasome and several natural compounds with proteasome inhibitory activity, and will discuss the potential use of these compounds for the prevention and treatment of human cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537678      PMCID: PMC3303152          DOI: 10.2174/138920308784533998

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  164 in total

Review 1.  Ubiquitin-mediated proteolysis: biological regulation via destruction.

Authors:  A Ciechanover; A Orian; A L Schwartz
Journal:  Bioessays       Date:  2000-05       Impact factor: 4.345

2.  Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.

Authors:  Grant Dewson; Roger T Snowden; Jason B Almond; Martin J S Dyer; Gerald M Cohen
Journal:  Oncogene       Date:  2003-05-01       Impact factor: 9.867

Review 3.  The ubiquitin-proteasome system.

Authors:  Dipankar Nandi; Pankaj Tahiliani; Anujith Kumar; Dilip Chandu
Journal:  J Biosci       Date:  2006-03       Impact factor: 1.826

4.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27.

Authors:  Y Katayose; M Kim; A N Rakkar; Z Li; K H Cowan; P Seth
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

5.  Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells.

Authors:  Deborah Kuhn; Wai Har Lam; Aslamuzzaman Kazi; Kenyon G Daniel; Shuojing Song; Larry M C Chow; Tak Hang Chan; Q Ping Dou
Journal:  Front Biosci       Date:  2005-05-01

Review 6.  Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation.

Authors:  P Masdehors; H Merle-Béral; H Magdelénat; J Delic
Journal:  Leuk Lymphoma       Date:  2000-08

7.  Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.

Authors:  B Li; Q P Dou
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

8.  Genistein suppresses proliferation and MET oncogene expression and induces EGR-1 tumor suppressor expression in immortalized human breast epithelial cells.

Authors:  Keith Singletary; Allison Ellington
Journal:  Anticancer Res       Date:  2006 Mar-Apr       Impact factor: 2.480

9.  Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.

Authors:  Kedar Hastak; Sanjay Gupta; Nihal Ahmad; Mukesh K Agarwal; Munna L Agarwal; Hasan Mukhtar
Journal:  Oncogene       Date:  2003-07-31       Impact factor: 9.867

10.  Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands.

Authors:  M G Hertog; P C Hollman; M B Katan; D Kromhout
Journal:  Nutr Cancer       Date:  1993       Impact factor: 2.900

View more
  32 in total

1.  Reliance of Wolbachia on High Rates of Host Proteolysis Revealed by a Genome-Wide RNAi Screen of Drosophila Cells.

Authors:  Pamela M White; Laura R Serbus; Alain Debec; Adan Codina; Walter Bray; Antoine Guichet; R Scott Lokey; William Sullivan
Journal:  Genetics       Date:  2017-02-03       Impact factor: 4.562

2.  Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines.

Authors:  Ana-Matea Mikecin; Leslie R Walker; Marija Kuna; Drazen Raucher
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

3.  PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.

Authors:  Shinrye Lee; Yu-Mi Jeon; Sun Joo Cha; Seyeon Kim; Younghwi Kwon; Myungjin Jo; You-Na Jang; Seongsoo Lee; Jaekwang Kim; Sang Ryong Kim; Kea Joo Lee; Sung Bae Lee; Kiyoung Kim; Hyung-Jun Kim
Journal:  Autophagy       Date:  2019-11-05       Impact factor: 16.016

4.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

5.  Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors.

Authors:  Sheng Biao Wan; Huanjie Yang; Zhongyuan Zhou; Qiuzhi Cindy Cui; Di Chen; Jyoti Kanwar; Imthiyaz Mohammad; Q Ping Dou; Tak Hang Chan
Journal:  Int J Mol Med       Date:  2010-10       Impact factor: 4.101

6.  Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.

Authors:  Olga A Issaenko; Alexander Yu Amerik
Journal:  Cell Cycle       Date:  2012-05-01       Impact factor: 4.534

Review 7.  Natural products against cancer angiogenesis.

Authors:  El Bairi Khalid; El-Meghawry El-Kenawy Ayman; Heshu Rahman; Guaadaoui Abdelkarim; Agnieszka Najda
Journal:  Tumour Biol       Date:  2016-09-20

8.  Celastrol and Its Role in Controlling Chronic Diseases.

Authors:  Shivaprasad H Venkatesha; Kamal D Moudgil
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

9.  The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions.

Authors:  D Jantas; A Roman; J Kuśmierczyk; E Lorenc-Koci; J Konieczny; T Lenda; W Lasoń
Journal:  Neurotox Res       Date:  2013-01-10       Impact factor: 3.911

10.  Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.

Authors:  Huanjie Yang; Ping Zhou; Hongbiao Huang; Di Chen; Ningfang Ma; Qiuzhi Cindy Cui; Shouxing Shen; Weihua Dong; Xiaoyan Zhang; Wen Lian; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.